

Tamoxifen, Raloxifene Upheld for Prevention

BY KERRI WACHTER

WASHINGTON — Tamoxifen and raloxifene offer women at high risk of developing breast cancer two effective options to prevent the disease, based on 8 years of follow-up data for more than 19,000 women in the STAR trial.

While tamoxifen proved significantly more effective in preventing invasive breast cancer, there was no significant difference between the two drugs in preventing non-invasive breast cancer. And raloxifene (Evista) had significantly less toxicity, including endometrial cancer, thromboembolic complications, and cataracts.

"These data are good news for postmenopausal women who want to reduce their risk of breast cancer," said Dr. D. Lawrence Wickerham, associate chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP). "The important message is that both [drugs]



"These data are good news for postmenopausal women who want to reduce their risk of breast cancer."

DR. WICKERHAM

are options. The decision is a shared one between the patient and her physician."

Dr. Wickerham presented the latest results for the Study of Tamoxifen and Raloxifene (STAR) trial during a late-breaker session at the annual meeting of the American Association for Cancer Research. The results were also published in the journal *Cancer Prevention Research* (April 19, 2010; doi: 10.1158/1940-6207.CAPR-10-0076).

Oncologists at the meeting expressed frustration that more women at high risk are not on the drugs, given the proven efficacy of the two selective estrogen receptor modulators (SERMs) in preventing breast cancer.

"I have to ask, why aren't the results of the BCPT [breast cancer prevention trial] and STAR trials more vigorously applied in clinical practice?" said Dr. Gabriel N. Hortobagyi, who was the discussant.

Dr. Wickerham echoed this frustration during a press conference. "I see women each week, at a high risk of breast cancer, and I will end up telling one or two of them... all too often... that they have breast cancer. I'd love for that part of my job to go away. These data are a step in that direction" said Dr. Wickerham, chief of the cancer genetics and prevention section at Allegheny General Hospital in Pittsburgh. The randomized, double-blind federally funded STAR trial included women at least 35 years of age with a 5-year predicted breast cancer risk of at least 1.66% (based on a modified version of the Gail model). Researchers from the NSABP randomized 19,747 women to receive either tamoxifen or raloxifene (*JAMA* 2006;295:2742-51).

The update includes 19,490 women—

9,736 on tamoxifen and 9,754 on raloxifene. The differences in numbers are due to a combination of loss during follow-up or follow-up data becoming available for women who were lost to follow-up in the original report. Women on tamoxifen received 20 mg/day and those on raloxifene received 60 mg/day.

At an average follow-up of 8 years, the relative risk of invasive breast cancer on raloxifene, compared with tamoxifen was

1.24, which was significant ($P = .01$). Both drugs reduced the risk of invasive breast cancer by roughly 50% in the original report (median follow-up 47 months).

"We have estimated, however, that this difference in the raloxifene-treated group represents 76% of tamoxifen's chemopreventative benefit, which translates into a 38% reduction in invasive breast cancers," Dr. Wickerham said.

In the 2006 report, raloxifene (81

events) did not appear to be as effective as tamoxifen (57 events) in preventing noninvasive breast cancer ($P = .052$). "Now with additional follow-up, those differences have narrowed," he said. At 8 years, there was no statistical significance between the two groups with a risk ratio of 1.22 ($P = .12$). The relative risk of 1.22 favors tamoxifen, but raloxifene preserves 78% of the chemopreventative benefit of tamoxifen. This

Mealtime therapy can fit into cubicle #8.



Humalog® KwikPen™, part of the Humalog® approach, is designed to help fit mealtime therapy into your patient's life. It's small, doesn't need refrigeration after the first use, and can be used almost anywhere. To find out more, go to www.Humalog.com or see your Lilly sales representative.

Humalog is for use in patients with diabetes mellitus for the control of hyperglycemia. Hypoglycemia is the most common adverse effect associated with insulins, including Humalog.

For complete safety profile, please see Important Safety Information and Brief Summary of full Prescribing Information on adjacent pages.

Please see full user manual that accompanies the pen.

Humalog KwikPen™
insulin lispro injection (rDNA origin)



translates to raloxifene preventing 39% of noninvasive breast cancers.

Raloxifene maintained its toxicity advantage. The relative risk of uterine cancers with raloxifene vs. tamoxifen was 0.55. There also were twice as many hysterectomies for benign disease in the tamoxifen group. This was due in part to an 80% increase in hyperplasia of the endometrium that occurred in women on tamoxifen, Dr. Wickerham said.

Both drugs increase the risk of thromboembolic complications, but there were significantly fewer ($P = .007$) of these events in women on raloxifene (154),

compared with tamoxifen (202).

Dr. Hortobagyi, director of the breast cancer research program at the University of Texas M.D. Anderson Cancer Center in Houston, identified factors that may be responsible for limited use of tamoxifen and raloxifene for prevention. He cited misinformation about the drugs, fears about toxicities, limited



high-risk prediction tools, lack of a marker or measurement to monitor for risk reduction, cost, and insufficient public and professional education about the drugs.

'The challenge today is how to communicate to the public to enhance the utilization of SERMs.'

DR. HORTOBAGYI

for adverse effects for effective preventative interventions," he said, noting discrepan-

cy between what is considered acceptable risk for other preventative drugs and SERMs. For example, drugs used to prevent hypertension and coronary artery disease have more and more serious adverse events than SERMs, he said.

"The challenge today is how to communicate to the public to enhance the utilization of SERMs and reduce further the incidence of breast cancer," he said. ■

Disclosures: The study was supported by the National Cancer Institute. Dr. Wickerham reported that he has consulted for Eli Lilly.

Indication

Humalog (insulin lispro injection [rDNA origin]) is for use in patients with diabetes mellitus for the control of hyperglycemia. Humalog should be used with longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

Important Safety Information

Humalog is contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients.

Humalog differs from regular human insulin by its rapid onset of action as well as a shorter duration of action. Therefore, when used as a mealtime insulin, Humalog should be given within 15 minutes before or immediately after a meal.

Due to the short duration of action of Humalog, patients with type 1 diabetes also require a longer-acting insulin to maintain glucose control (except when using an insulin pump). Glucose monitoring is recommended for all patients with diabetes.

The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. There are no adequate and well-controlled clinical studies of the use of Humalog in pregnant or nursing women.

Starting or changing insulin therapy should be done cautiously and only under medical supervision.

Hypoglycemia

Hypoglycemia is the most common adverse effect associated with insulins, including Humalog. Hypoglycemia can happen suddenly, and symptoms may be different for each person and may change from time to time. Severe hypoglycemia can cause seizures and may be life-threatening.

Other Side Effects

Other potential side effects associated with the use of insulins include: hypokalemia, weight gain, lipodystrophy, and hypersensitivity. Systemic allergy is less common, but may be life-threatening. Because of the difference in action of Humalog, care should be taken in patients in whom hypoglycemia or hypokalemia may be clinically relevant (eg, those who are fasting, have autonomic neuropathy or renal impairment, are using potassium-lowering drugs, or taking drugs sensitive to serum potassium level).

For additional safety profile and other important prescribing considerations, see accompanying Brief Summary of full Prescribing Information.

Please see full user manual that accompanies the pen.

Humalog® is a registered trademark of Eli Lilly and Company and is available by prescription only.

Humalog® KwikPen™ is a trademark of Eli Lilly and Company and is available by prescription only.

Humalog

insulin lispro injection (rDNA origin)